CHICAGO – Patients with severe acne are missing out on the skin-clearing benefits of oral contraceptives and need to know that OCs can be prescribed for acne without a pelvic examination by a gynecologist, according to Dr. Bethanee Schlosser.

"When talking to teens and their parents, it's important to explain that a pelvic exam is not necessary before giving these medications to young women," she said.

©Tina Sbrigato/iStockphoto.com Patients may be reluctant to ask for oral contraceptives to treat their acne.

It appears that patients aren't privy to this information, and are reluctant to ask for oral contraceptives as acne medication.

"That may be the biggest hurdle keeping these patients from getting adequate treatment for their acne," she said.

In 2004, the World Health Organization released guidelines stating that pelvic exams and Pap smears are no longer required before administering combination oral contraceptives.

Dr. Schlosser noted, however, that she does ask all of her female patients when they had their last full gynecologic exam, Pap smear included, and encourages them to stay current.

Oral Contraceptives

Three combination oral contraceptives are approved for the treatment of acne in women in the United States: ethinyl estradiol and norgestimate, ethinyl estradiol and norethindrone, and ethinyl estradiol and drospirenone.

Drospironone, an analogue of spironolactone, reduces sebum production and increases sex hormone–binding globulin, thus reducing circulating androgens, Dr. Schlosser said. "Some women will come to me, though, and say that their ob.gyn. has told them they can’t take any pill containing drospirenone or spironolactone," because of its possible effect on potassium levels, especially in combination with other drugs that increase serum potassium (ACE inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, heparin, aldosterone antagonists, and nonsteroidal anti-inflammatories).

Dr. Schlosser pointed to a 2009 study of 27 women with either severe papular or nodulocystic acne who were treated with a combined oral contraceptive containing 30 mg ethinyl estradiol, 3 mg drospirenone, and 100 mg spironolactone. None of the patients had a significant elevation in serum potassium level; there were no reports of adverse events serious enough to require discontinuation of treatment. At follow up, 85% of subjects were entirely clear of acne lesions or had excellent improvement, 7% were mildly improved, and 7% were not improved (J. Am. Acad. Derm. 2880;58:60-2). 

A 2008 study looked only at the risk of hyperkalemia among 22,429 women who used the drospirenone-containing contraceptive compared with 44,858 who used other oral contraceptives (Contraception 2008;78:377-83). There was no significant between-group difference in the incidence of hyperkalemia.

This type of treatment is not an overnight acne cure, Dr. Schlosser stressed. “I tell women you have to allow at least three cycles of use before you start to judge efficacy. Patients can continue to get more benefit from 3-6 months of use, too.”

08/27/10